Effects of the Deletion of Early Region 4 (E4) Open Reading Frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on Virus-Host Cell Interaction, Transgene Expression, and Immunogenicity of Replicating Adenovirus HIV Vaccine Vectors

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Thomas, Michael A ^a   Song, Rui ^a   Demberg, Thorsten ^a   Vargas Inchaustegui, Diego A ^a   Venzon, David ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; E1A PROTEIN; E1B PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL CYCLE; CELLULAR IMMUNITY; CONTROLLED STUDY; E4 GENE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE PRODUCT; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; OPEN READING FRAME; PROGENY; TRANSGENE; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E4 PROTEINS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HIV; HOST-PATHOGEN INTERACTIONS; MICE; SEQUENCE DELETION; T-LYMPHOCYTES; TRANSGENES; VACCINATION; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84885452726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076344     Document Type: Article

References (54)

1. Patterson LJ, Robert-Guroff M, (2008) Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 8: 1347-1363.
2. Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, et al. (2012) Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 19: 629-637.
3. Haase AT, (2011) Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62: 127-139.
4. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, et al. (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3: 651-658.
5. Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, et al. (1998) Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol 72: 10275-10280.
6. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, et al. (2004) Protection against mucosal simian immunodeficiency virus SIV (mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78: 2212-2221.
7. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, et al. (2006) Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 353: 83-98.
8. Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, et al. (2007) A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 81: 3414-3427.
9. Bogers WM, Davis D, Baak I, Kan E, Hofman S, et al. (2008) Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382: 217-225.
10. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, et al. (2005) Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79: 10200-10209.
11. Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, et al. (2012) Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 7: e31177.
12. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, et al. (2013) Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis.
13. Jones N, Shenk T, (1979) Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17: 683-689.
14. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, et al. (2002) Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269: 273-318.
15. Patterson LJ, Prince GA, Richardson E, Alvord WG, Kalyan N, et al. (2002) Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 292: 107-113.
16. Huang MM, Hearing P, (1989) Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J Virol 63: 2605-2615.
17. Bridge E, Ketner G, (1989) Redundant control of adenovirus late gene expression by early region 4. J Virol 63: 631-638.
18. Thomas MA, Broughton RS, Goodrum FD, Ornelles DA, (2009) E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus. J Virol 83: 2406-2416.
19. Sohn SY, Hearing P, (2012) Adenovirus regulates sumoylation of Mre11-Rad50-Nbs1 components through a paralog-specific mechanism. J Virol 86: 9656-9665.
20. Ullman AJ, Reich NC, Hearing P, (2007) Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J Virol 81: 4744-4752.
21. Shepard RN, Ornelles DA, (2004) Diverse roles for E4orf3 at late times of infection revealed in an E1B 55-kilodalton protein mutant background. J Virol 78: 9924-9935.
22. Lusky M, Grave L, Dieterle A, Dreyer D, Christ M, et al. (1999) Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J Virol 73: 8308-8319.
23. Kanopka A, Muhlemann O, Petersen-Mahrt S, Estmer C, Ohrmalm C, et al. (1998) Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins. Nature 393: 185-187.
24. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, et al. (2005) Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J 24: 1211-1221.
25. Medghalchi S, Padmanabhan R, Ketner G, (1997) Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms. Virology 236: 8-17.
26. Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, et al. (2000) Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74: 11427-11436.
27. Cheng SM, Lee SG, Ronchetti-Blume M, Virk KP, Mizutani S, et al. (1992) Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 66: 6721-6727.
28. Shepherd SE, Howe JA, Mymryk JS, Bayley ST, (1993) Induction of the cell cycle in baby rat kidney cells by adenovirus type 5 E1A in the absence of E1B and a possible influence of p53. J Virol 67: 2944-2949.
29. Parreno M, Garriga J, Limon A, Albrecht JH, Grana X, (2001) E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes. Oncogene 20: 4793-4806.
30. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, et al. (1988) Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129.
31. Spitkovsky D, Jansen-Durr P, Karsenti E, Hoffman I, (1996) S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Oncogene 12: 2549-2554.
32. Shen T, Huang S, (2012) The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem 12: 631-639.
33. Zheng X, Rao XM, Gomez-Gutierrez JG, Hao H, McMasters KM, et al. (2008) Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 82: 3415-3427.
34. Hwang HC, Clurman BE, (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786.
35. Chanda PK, Natuk RJ, Mason BB, Bhat BM, Greenberg L, et al. (1990) High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology 175: 535-547.
36. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, et al. (2001) Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J Virol 75: 699-709.
37. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J, (1987) IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165: 64-69.
38. Gahery-Segard H, Juillard V, Gaston J, Lengagne R, Pavirani A, et al. (1997) Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27: 653-659.
39. Braithwaite AW, Murray JD, Bellett AJ, (1981) Alterations to controls of cellular DNA synthesis by adenovirus infection. J Virol 39: 331-340.
40. Lemay P, Collyn-D'Hooghe M, (1984) Flow cytophotometric and time-lapse cinematographic study of human cells infected by adenovirus type 2 wild-type and two DNA-negative temperature-sensitive mutants. J Gen Virol 65 (Pt 8): 1419-1423.
41. Murray JD, Berger ML, Taylor IW, (1981) Flow cytometric analysis of DNA content of mouse liver cells following in vivo infection by human adenovirus type 5. J Gen Virol 57: 221-225.
42. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, et al. (2006) E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 5: 2244-2252.
43. Mandal S, Freije WA, Guptan P, Banerjee U, (2010) Metabolic control of G1-S transition: cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol 188: 473-479.
44. Kaplan JM, Armentano D, Scaria A, Woodworth LA, Pennington SE, et al. (1999) Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. J Virol 73: 4489-4492.
45. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM, (1999) Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 162: 5049-5052.
46. Song W, Wagle NM, Banh T, Whiteford CC, Ulug E, et al. (1997) Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocks the assembly of peptide-MHC class II complexes. Int Immunol 9: 1709-1722.
47. Shurin GV, Tourkova IL, Chatta GS, Schmidt G, Wei S, et al. (2005) Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol 174: 3394-3400.
48. Chang SK, Park B, Shin J, Ahn JH, Kim IH, et al. (2002) Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells. Mol Cells 14: 130-135.
49. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, et al. (1998) Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396: 373-376.
50. Samstag Y, Nebl G, (2003) Interaction of cofilin with the serine phosphatases PP1 and PP2A in normal and neoplastic human T lymphocytes. Adv Enzyme Regul 43: 197-211.
51. Bruhns P, (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
52. Hidajat R, Kuate S, Venzon D, Kalyanaraman V, Kalisz I, et al. (2010) Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine 28: 3963-3971.
53. Adams RL, Lindsay JG, (1967) Hydroxyurea reversal of inhibition and use as a cell-synchronizing agent. J Biol Chem 242: 1314-1317.
54. Pozarowski P, Darzynkiewicz Z, (2004) Analysis of cell cycle by flow cytometry. Methods Mol Biol 281: 301-311.